Chanticleer Holdings Inc Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics - M&A Call Transcript
Hello, and thank you for standing by. Welcome to the Chanticleer Holdings conference call. As a reminder, all participants are in a listen-only mode, and the conference is being recorded.
At this time, I would like to turn the conference over to Jason Assad, Investor Relations with Chanticleer Holdings. Please go ahead.
Thank you, Michelle. Good morning and welcome to the Chanticleer Holdings conference call. With this today are Mike Pruitt, Chanticleer's Chairman; and Dr. Pankaj Mohan, Founder and Chief Executive Officer of Sonnet BioTherapeutics.
Before I turn this call over to management, please remember that during the course of this conference call, we will make certain forward-looking statements. Any statements that are not historical facts contained in this call are forward-looking statements, as the term is defined under the Private Securities Litigation Reform Act of 1995, better known as the PSLRA, which statements may be identified by words such as expects, plans, projects, may,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
